



AMF 14T

THE BIOLOGICAL BULLETIN

RECEIVED

NOV 16 1984

CLINICAL RESEARCH

Marketing Bulletin 17-84
12 November 1984

KOATE-HT UPDATE

Attached to this bulletin are the following papers:

- "Viral Inactivation Studies", M. Mozen, Cutter Laboratories
- "Recovery and Inactivation of Infectious Retroviruses Added to Factor VIII Concentrates", J. Levy, The Lancet.
- KOATE-HT Human Virus Inactivation Data, Dr. J.A. Levy (private communications) Center for Disease Control Publication
- National Hemophilia Foundation's Recommendation Concerning AIDS and Hemophilia, ABRA Newsletter
- Announcement of Discontinuance of Core Antibody Screening of Plasma Donors

These should be placed in Section "Why Heat" in your KOATE-HT Release Manual for ready reference.

Viral Inactivation Studies

Dr. Milt Mozen, Director of Research and Development - Biological Products, presented a paper to the World Federation of Hemophilia Congress on viral inactivation studies on Cutter concentrates. A copy of this booklet was sent to each participant attending the Congress in Rio de Janeiro.

115 4006

The following viruses have been tested with our heat-treated product since the original data on cytomeglovirus, herpes simplex virus, vesicular stomatitis virus, and sindbis virus were reported:

- Feline Leukemia Virus (a retrovirus) inactivation
- Simian AIDS virus (a retrovirus) inactivation
- Mouse C retrovirus reduced to non-infective levels
- Non-A, Non-B (NANB) Hutchinson strain inactivation
- Non-A, Non-B (NANB) endogenous, one type, inactivation

The retrovirus data is significant because many experts agree that the AIDS virus is either related to, or is, a series of retroviruses. At the hemophilia Congress, a good deal of attention was given to our simian AIDS data by key physicians. Remember Cutter's data on these retroviruses is the first performed in the industry.

The NANB data is significant in that we utilized a known reproducible strain (Hutchinson) and Cutter's heat-treating process inactivated 2500 chimp infective doses (CIDS). Also, the fact that we were able to inactivate an endogenous amount of NANB strengthens our findings.

In slide 13 on page 18 of the booklet, you can add at the top line between weeks 22 & 24 a (+) sign. Thus, this information validates the test design, protocol and test results.

Mouse C Retroviruses

This paper, by Dr. J.A. Levy, was published in the 29 September 1984 issue of the Lancet. It represents the first successful study demonstrating the effectiveness of Cutter's heat-treated process in inactivating an animal retrovirus. These findings were important enough to receive media attention in the U.S. due to the concern about AIDS.

115 4007

Dr. Levy concluded that this mouse C retrovirus was inactivated by the unique Cutter heat-treated process. It should also be noted that in Table II on page 723 of the Lance article the IP/ml figure opposite the 72 hour interval should read 10 to the 0.2 power not 10 to the 10.2 power. This typographical error should be corrected on your copy.

LAV and ARV Data

The page titled "KOATE-HT Human Virus Inactivation Data", offers a summary of independent studies done by the Center for Disease Control of the U.S.A. on the lymphadenopathy associated virus (LAV) and by Dr. J.A. Levy on the AIDS-related virus (ARV).

As noted in both studies, using the Cutter process of treating AHF concentrates, the retroviruses LAV and ARV were inactivated. CDC in an independent research study using the LAV retrovirus, first isolated by the Pasteur Institute in France, was able to demonstrate that the LAV does not survive the unique Cutter heat-treating process. Dr. Levy performed tests with the ARV which his team at the University of California, San Francisco isolated and preliminary results suggest that Cutter's heat treatment process virtually inactivated the AIDS related virus (ARV).

NHF Heat-Treat Announcement

The Medical and Scientific Advisory Council of the National Hemophilia Foundation (NHF) after the NHF Meeting in Rochester, N.Y. released the attached medical bulletin. They state in Section C of Paragraph 1 of the bulletin that those treating hemophiliacs and using concentrates should strongly consider changing to heat-treated products. Apparently this decision was based on preliminary reports of the effectiveness of heat treatment against AIDS-like viruses.

Discontinuance of Hepatitis B Core Screening

As a result of the success of our heating process against viral contaminants, the anti-hepatitis B core tests will no longer be performed.

115 4008

Based on the best information available, it was decided by Cutter management that in the future, Cutter will supply only KOATE-HT to customers. Some physicians remain skeptical of heat-treated AHF because the data are still preliminary. For those physicians Cutter will supply KOATE (non-heat-treated). Please check with your Area Marketing Manager if you have questions regarding product availability.

Best Regards,

GRO-C

Gary Mull
Product Manager

GM/cfg

115 4006